Diagnos Laboratorium Utama PT Tbk
IDX:DGNS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (56.7), the stock would be worth Rp495.72 (78% upside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 31.8 | Rp278 |
0%
|
| Industry Average | 56.7 | Rp495.72 |
+78%
|
| Country Average | 12.6 | Rp110.32 |
-60%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| ID |
D
|
Diagnos Laboratorium Utama PT Tbk
IDX:DGNS
|
347.5B IDR | 31.8 | 118.3 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
106.6B USD | 12.6 | 60.3 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
71B EUR | 12.6 | 14.1 | |
| US |
|
Cigna Corp
NYSE:CI
|
77B USD | 0 | 12.9 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.3B EUR | -25.1 | 18.4 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.5B EUR | 13.9 | 22.8 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.1B USD | 631 | 24.1 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21B USD | 23.3 | 20.6 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.6B EUR | 6.5 | 10.8 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
10.9B USD | 65.8 | -26.2 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 6 | 14 |
Market Distribution
| Min | 0.7 |
| 30th Percentile | 8.6 |
| Median | 12.6 |
| 70th Percentile | 24 |
| Max | 1 806 198.3 |
Other Multiples
Diagnos Laboratorium Utama PT Tbk
Glance View
PT Diagnos Laboratorium Utama Tbk engages in the provision of health support service. The company employs 54 full-time employees The company went IPO on 2021-01-15. The firm is engaged in providing health support services, such as health laboratories, other diagnostic drawing centers, blood testing laboratories, pharmaceutical warehouses, eye banks, sperm banks and blood banks, organ transplant banks, and other medical support services. The company operates through providing health services using laboratories segment. The Company’s products and services include clinical pathology laboratory, anatomy pathology laboratory, genomic laboratory, homecare health services, corporate health services, and Covid-19 checkup. The firm serves markets, such as Jakarta, Depok, Bali, Bandung, Bekasi, Padang, Makassar, Tangerang Selatan, Dumai, Batam, Purwakarta, Karawang, and Brebes. The company has branch offices in Ciputat (South Tangerang), Denpasar (Bali), Padang (West Sumatra), and Makassar, South Sulawesi.
